Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553392 · ClinicalTrials.gov registry record · NA
StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis
A NA study, sponsored by Stratpharma.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT05553392 is a NA study that was terminated before completion, run by Stratpharma. The registered enrollment target is 13 participants.
The verdict
NCT05553392, a NA study, was terminated before completion, sponsored by Stratpharma.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The aim of this study is to assess the efficacy and safety of StrataXRT® in comparison to standard of care (defined using the Common Terminology Criteria for Adverse Events \[CTCAE\], version 5.0) by assessing the severity of inguinal RD in patients receiving elective radiation therapy +/- systemic therapy to the bilateral inguinal nodes.
Interventions
- DRUG Aquaphor
- DEVICE StrataXRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2024-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05553392
The ClinicalTrials.gov registry entry for NCT05553392 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stratpharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aquaphor is the first listed.
NCT05553392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05553392 about?
NCT05553392 is a clinical study titled "StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis". The aim of this study is to assess the efficacy and safety of StrataXRT® in comparison to standard of care (defined using the Common Terminology Criteria for Adverse Events \[CTCAE\], version 5.0) by assessing the severity of inguinal RD in patients receiving elective radiation therapy +/- systemic ...
What is the current status of trial NCT05553392?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2022-11-01. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT05553392?
The interventions under investigation include: Aquaphor (DRUG), StrataXRT (DEVICE).
Who is sponsoring clinical trial NCT05553392?
This trial is sponsored by Stratpharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.